| Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis |
Ongoing |
Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care |
4 |
1F-MC-B007 |
Hira Hospital (Makkah) |
| Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma |
Ongoing |
DUPILUMAB |
4 |
LPS15834 |
King Fahad Medical City (Riyadh) |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS |
Ongoing |
DUPILUMAB |
4 |
OBS15990 |
King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) |
Ongoing |
Drug choice as per treating physician which is not limited per the protocol |
4 |
H19-940 |
Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Multinational, Prospective, Observational Study of theEffectiveness, Healthcare Resource Utilization and Costsin Patients with Rheumatoid Arthritis ReceivingBaricitinib, Targeted Synthetic or BiologicDisease-Modifying Therapies" |
Ongoing |
Baricitinib |
4 |
I4V-MCB009 |
Specialized Medical Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Takhassusi (Riyadh) |
| A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with Type 2 diabetes mellitus, treated with iGlarLixi fixed ratio combination (SOLIQUA®) before, during and after the period of Ramadan (SoliRam Study) |
Ongoing |
Soliqua® Solostar |
4 |
OBS16049 |
University District Hospital (Jeddah), Alzafer Hospital (Najran), Ghassan Najeeb Pharaon hospital (Jeddah) |
| Guidelines Oriented Approach to Lipid lowering Quality Enhancement Research Initiative (GOAL QuERI) International |
Ongoing |
any SFDA registered anti-hyperlipidemic product |
4 |
CHRC2019 |
King Fahd Armed Forces Hospital (Jeddah), King Fahd Military Medical Complex (Dhahran), King Abdullah Medical Complex (Jeddah), King Fahad Hospital (Jeddah), King Fahad Genaral Hospital (Medina), King Khaled General Hospital (Hafar Al Batin), Royal Commission Hospital Jubail |
| Vortioxetine effectiveness overview for the treated MDE patients in Saudi Arabia |
Ongoing |
BRINTELLIX 20 mg film-coated tablet/ BRINTELLIX 10 mg film-coated tablet |
4 |
18620N |
King Abdulaziz University Hospital (Jeddah), Saudi German Hospital (Jeddah), Dr. Erfan & Bagedo General Hospital (Jeddah), University Medical Center (Riyadh), Psych care Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Al Moosa Specialized Hospital (al ahsa), King Fahad Medical City (Riyadh), Almana Hospital (Dammam), King Abdullah Medical Complex (Jeddah), Jeddah psychiatric hospital, Elite Medical Complex (Makkah) |
| "Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)" |
Ongoing |
• Ceftriaxone • Piperacillin Tazobactam • Azithromycin • Interferon β1-a • Hydrocortisone sodium suc.• Hydroxychloroquine • OSELTAMIVIR • Lopinavir-Ritonavir |
3 |
CT20/001/R |
King Abdulaziz Medical City NG (Riyadh) |
| A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis – The MuSicalE STUDY |
Ongoing |
Ocrelizumab (Ocrevus) |
4 |
MN39889 |
King Abdulaziz Medical City NG (Riyadh) |
